Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events
Benzinga Newsdesk 4 days ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
LUCIDITY met its prespecified primary endpoint; avexitide reduced the composite Level 2/3 hypoglycemic event rate by 55% compared to placebo (p=0.000003)Avexitide showed consistent, highly statistically significant
- LUCIDITY met its prespecified primary endpoint; avexitide reduced the composite Level 2/3 hypoglycemic event rate by 55% compared to placebo (p=0.000003)
- Avexitide showed consistent, highly statistically significant reductions across all prespecified, multiplicity-controlled secondary event-rate endpoints vs. placebo
- Avexitide was generally well-tolerated with a favorable safety profile; adverse events during the double-blind treatment period were generally mild to moderate in severity
